The Implantable Cardioverter Defibrillator Market is segmented by Type (Transvenous Implantable Cardioverter Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs), Cardiac Resynchronization Therapy Defibrillator (CRT-D)), End User (Hospitals, Ambulatory Surgical Centers), and Region (North America, Europe, Asia-Pacific, and the Rest of the World). This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global market.
What is an implantable cardioverter-defibrillator?
An implantable cardioverter-defibrillator (ICD) is a device implantable inside the body that can perform defibrillation, cardioversion, and correct pacing of the heart. The ICD is used in treating sudden cardiac arrest caused due to ventricular fibrillation, cardiac arrhythmias, and pulseless ventricular tachycardia. The device is, therefore, capable of correcting most life-threatening cardiac arrhythmias.
Key players operating in the implantable cardioverter-defibrillator market are-
Philips Healthcare (Netherlands)
Defibtech, LLC (US)
Asahi Kasei Corporation (Japan)
LivaNova Plc (UK)
Cardiac Science (US)
CU Medical System Inc (Germany)
The growing prevalence of cardiovascular diseases, the rise in the geriatric population is the key driving factor for the product demand. Cardiovascular diseases (CVDs) are the prime cause of death. More than 75% of deaths occur in low and middle-income countries. The increased applications and acceptance of the Implantable Cardioverter Defibrillator (ICD) are accelerating market growth. The ICD detects and stops abnormal heartbeats (arrhythmias). The device monitors the patient’s heartbeat and delivers electrical pulses to restore a normal heart rhythm when necessary. The rising advancements in subcutaneous ICD technology will pave the way for profitable opportunities in the market economy.
The market has been classified into Transvenous Implantable Cardioverter Defibrillator (T-ICDs), Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs), and Cardiac Resynchronization Therapy Defibrillator (CRT-D). The Subcutaneous Implantable Cardioverter Defibrillator (S-ICDs) segment accounted for the significant market share in 2020. A subcutaneous implantable cardioverter-defibrillator (S-ICD) is an electronic device that constantly monitors your heart rhythm. When it detects a very fast, abnormal heart rhythm, it delivers energy to the heart muscle. This causes the heart to beat in a normal rhythm again, across the globe, which further boosts the segment growth.
The market in the Asia Pacific accounted for the largest share in 2020 and is projected to continue its dominance during the review period. This is mainly attributed to growth in the geriatric populace, the large patient population, strong incidence of cardiovascular diseases, and call for increased battery life in ICD devices, improved healthcare workflow organization, further proliferate the regional growth.
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to firstname.lastname@example.org.